Skip to main content

Table 2 Comparison of the matched derivation and validation cohorts

From: Temporal validation of the CT-PIRP prognostic model for mortality and renal replacement therapy initiation in chronic kidney disease patients

  

Nodes

All nodes

1

2

3

4

5

6

7

N (%)

D

2051 (100.0)

217 (10.6)

347 (16.9)

98 (4.8)

220 (10.7)

75 (3.7)

388 (18.9)

706 (34.4)

V

2051 (100.0)

217 (10.6)

347 (16.9)

98 (4.8)

220 (10.7)

75 (3.7)

388 (18.9)

706 (34.4)

eGFR change

D

−1.22;4.22

−2.27;5.19

−1.49;4.11

−3.25;4.72

−1.32;4.56

−1.79;5.31

−0.58;4.31

−0.86;4.15

(median; IQR)

V

−1.11;4.41

− 3.43;5.86

−2.09;4.27

− 2.00;4.94

− 0.76;4.04

− 1.11;5.17

−0.37;4.26

− 0.61;3.73

M-W test

0.7, p = .482

1.8, p = .080

1.8, p = .072

−1.2, p = .238

−1.8, p = .072

−2.1, p = .040

−0.5, p = .647

−0.8, p = .414

baseline eGFR

D

27.1;16.1

42.7;13.9

23.3;10.4

17.5;10.4

31.3;23.1

30.6;16.9

24.2;11.6

28.0;15.5

(median; IQR)

V

29.6;18.7

45.5;15.1

23.1;9.6

17.5;10.4

39.3;24.0

38.2;21.7

25.4;14.1

31.8;16.6

M-W test

−6.0, p < .001

−2.2, p = .030

0.7, p = .490

−0.1, p = .922

−4.2, p < .001

−3.1, p = .002

−2.3, p = .023

−5.4, p < .001

PO4

D

3.70;0.90

3.50;0.90

3.70;0.70

4.90;0.80

3.70;1.00

4.00;1.00

3.90;0.75

3.50;0.90

(median; IQR)

V

3.50;0.90

3.40;0.90

3.60;0.70

4.80;0.60

3.40;0.95

3.70;0.70

3.70;0.80

3.30;0.80

M-W test

7.5, p < .001

1.6, p = .111

2.9, p = .004

1.2, p = .223

3.6, p = <.001

2.7, p = .008

4.6, p < .001

4.7, p < .001

Age

D

74.0;14.0

67.0;16.9

72.9;14.9

66.5;19.9

58.6;16.1

63.5;7.7

78.5;9.4

78.3;9.0

(median; IQR)

V

74.8;13.0

68.5;16.4

75.0;13.2

72.8;16.8

59.9;15.4

63.0;8.9

78.5;8.9

77.5;8.7

M-W test

−1.7, p = .085

−1.5, p = .137

−2.3, p = .019

−2.0, p = .043

−1.3, p = .182

1.0, p = .297

−1.0, p = .300

1.2, p = .238

Diabetes

D

668 (32.6)

98 (45.2)

129 (37.2)

48 (48.9)

0 (0)

73 (100.0)

110 (28.3)

208 (29.5)

n(%)

V

782 (38.1)

118 (54.4)

164 (47.0)

47 (48.0)

0 (0)

73 (100.0)

144 (37.1)

235 (33.3)

χ2 test

13.9, p = <.001

3.7, p = .055

6.8, p = .009

0.02, p = .886

–

–

6.8, p = .009

2.4, p = .121

Male gender

D

1340 (65.3)

161 (74.2)

235 (67.7)

49 (50.0)

139 (63.2)

50 (66.7)

0 (0)

694 (100.0)

n(%)

V

1372 (66.9)

170 (78.3)

246 (70.9)

47 (48.0)

147 (66.8)

56 (74.7)

0 (0)

694 (100.0)

χ2 test

1.1, p = .291

1.0, p = .310

0.8, p = .365

0.1, p = .775

0.6, p = .424

1.2, p = .282

–

–

  1. Abbreviations: D = derivation cohort; V = validation cohort; M-W test = Mann-Whitney test
  2. Missing data were found only in the serum phosphate variable (19.4% in the derivation cohort, 19.8% in the validation cohort)